PALO ALTO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq: AFFY) today announced that several presentations featuring Hematide, the company’s lead product candidate in development globally with Takeda Pharmaceutical Company Limited for the treatment of anemia, will be presented at the American Society of Nephrology Renal Week 2007 in San Francisco between October 31 - November 5, 2007. The three data presentations include results of the use of Hematide™ to treat anemia in chronic kidney disease (CKD) patients on dialysis, results of Hematide in CKD patients in the predialysis setting, and a study of Hematide to treat pure red cell aplasia (PRCA). This study on PRCA will be presented at an oral presentation session by Iain C. Macdougall, M.D., Hematide clinical trial investigator, consultant nephrologist and honorary senior lecturer in the Department of Renal Medicine at King’s College Hospital in London. PRCA, a rare autoimmune disorder, occurs when the body produces neutralizing antibodies to recombinant human erythropoietin (EPO), thus suppressing the production of red blood cells by the bone marrow.
